Machine signal
Active cluster sell — 5 distinct insiders, $21.6M, window ends Jul 9, 2026.
Figures computed from official regulatory filings — .
Analysttarget 124 USD (+0%) · consensus 4.73/5 · 11 buy · 0 hold · 0 sell
Ownershipinsiders 2.78% · institutions 113.3% · short 6.2% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Nuvalent, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
3 buys609 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Flynn James Etrack record | Other | $80.6M | Unusual size | SEC |
| Flynn James Etrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Flynn James Etrack record | Other | $1B | Unusual size | SEC |
| Flynn James Etrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Flynn James Etrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Flynn James Etrack record | Other | $638.1K | SEC |
| Flynn James Etrack record | OtherD (derivative) | $337M | Unusual size | SEC |
| Flynn James Etrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Flynn James Etrack record | Other | $1B | Unusual size | SEC |
| Flynn James Etrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Flynn James Etrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Flynn James Etrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Flynn James Etrack record | Other | $638.1K | SEC |
| Flynn James Etrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Flynn James Etrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Flynn James Etrack record | OtherD (derivative) | $337M | Unusual size | SEC |
| Flynn James Etrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Flynn James Etrack record | Other | $427.1K | SEC |
| Protopapas Anna | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Srivastava Sapna | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Srivastava Sapna | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Wheeler Cameron | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Wheeler Cameron | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Porter James Richard | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Miller Deborah Ann | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |